☆ 4.6 Review

20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults

DRUGS (2022)

Related references

Note: Only part of the references are listed.

Review Medicine, General & Internal

The 20-valent pneumococcal conjugate vaccine (PCV20): expected added value

Esther Janssens et al.

Summary: This review assesses the potential impact of implementing the investigational 20-valent pneumococcal conjugate vaccine (PCV20) in the vaccination programs of Belgium and Europe. The study finds that PCV20 has the potential to prevent more pneumococcal disease than existing vaccines, but further research is needed to confirm its effectiveness and safety.

ACTA CLINICA BELGICA (2023)

Add to Collection

Article Immunology

Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years

Brandon Essink et al.

Summary: The 20-valent pneumococcal conjugate vaccine (PCV20) has shown to be safe and well tolerated, with immunogenicity comparable to that of the 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide vaccine. PCV20 is expected to provide expanded protection against pneumococcal disease in adults.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Letter Respiratory System

A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany

Christina Bahrs et al.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

Miwako Kobayashi et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Article Immunology

Impact of Pneumococcal Conjugate Vaccines on Antibiotic-Nonsusceptible Invasive Pneumococcal Disease in the United States

Kristina L. Bajema et al.

Summary: The incidence of antibiotic-nonsusceptible invasive pneumococcal disease (NS-IPD) has decreased in the United States after the introduction of 7- and 13-valent pneumococcal conjugate vaccines (PCVs). However, there has been an increase in nonvaccine type NS-IPD, particularly among older adults. The use of higher valency PCVs containing the common nonsusceptible serotypes could help further reduce NS-IPD.

JOURNAL OF INFECTIOUS DISEASES (2022)

Add to Collection

Article Immunology

Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age

Donald Hurley et al.

Summary: This study evaluated the safety and immunogenicity of a 20-valent PCV in adults aged 60 to 64 without prior pneumococcal vaccination. Results showed that PCV20 was well tolerated and elicited robust immune responses against all serotypes in this age group, demonstrating its potential to expand pneumococcal disease protection.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era

Sara de Miguel et al.

Summary: The study analyzed the invasive pneumococcal disease cases in children and adults from 2009 to 2019, as well as the impact of different vaccine strategies. It found that PCV13 reduced disease burden in both children and adults, but an increase in serotype 8 in adults was observed.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥ 65 years of age with different prior pneumococcal vaccination

Kevin Cannon et al.

Summary: The study demonstrated that PCV20 is well tolerated and immunogenic in adults over 65 years of age with a history of different pneumococcal vaccine regimens, showing robust immune responses to the 20 vaccine serotypes a month after vaccination.

VACCINE (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States

David Fitz-Patrick et al.

Summary: The study evaluated the safety and immunogenicity of a 20-valent PCV and a complementary 7-valent PCV in healthy Japanese adults. Results showed robust immune responses in both PCV20 and cPCV7 groups at 1 month post-vaccination, with mild to moderate local and systemic reactions.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)

Add to Collection

Article Immunology

The Evolution and Distribution of Pneumococcal Serotypes in Adults Hospitalized With Community-Acquired Pneumonia in Spain Using a Serotype-Specific Urinary Antigen Detection Test: The CAPA Study, 2011-2018

Antoni Torres et al.

Summary: After 8 years of introducing PCV13 vaccine in childhood immunization program in Spain, PCV13-VT caused a substantial proportion of CAP in Spanish immunocompetent adults. Improving direct PCV13 coverage of targeted adult populations could further reduce PCV13-VT burden, and introducing PCV20 could potentially increase the benefits even further.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults

Raul Isturiz et al.

Summary: This study identified a significant proportion of hospitalized adult CAP cases associated with PCV20-unique serotypes, showing the potential of PCV20 in addressing the burden of CAP caused by additional serotypes not covered by PCV13. UAD2 detection technology played a crucial role in identifying and differentiating these serotypes.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age

Nicola P. Klein et al.

Summary: The three different lots of PCV20 demonstrated robust and consistent immunogenicity, with safety and tolerability comparable to PCV13.

VACCINE (2021)

Add to Collection

Editorial Material Immunology

The proportion of contemporary invasive pneumococcal disease and pneumococcal pneumonia in UK adults reflected by serotypes included in the 13-valent pneumococcal conjugate vaccine and next generation higher valency pneumococcal conjugate vaccines in development

Andrew Vyse et al.

VACCINE (2020)

Add to Collection

Review Immunology

Sugar-Coated Killer: Serotype 3 Pneumococcal Disease

Jennifer N. Luck et al.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2020)

Add to Collection

Article Infectious Diseases

Adult vaccination for pneumococcal disease: a comparison of the national guidelines in Europe

C. Bonnave et al.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2019)

Add to Collection

Review Infectious Diseases

Making sense of differences in pneumococcal serotype replacement

Joseph A. Lewnard et al.

LANCET INFECTIOUS DISEASES (2019)

Add to Collection

Article Multidisciplinary Sciences

Limited indirect effects of an infant pneumococcal vaccination program in an aging population

Mark van der Linden et al.

PLOS ONE (2019)

Add to Collection

Article Immunology

Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults

Allison Thompson et al.

VACCINE (2019)

Add to Collection

Review Immunology

Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis

John M. McLaughlin et al.

VACCINE (2019)

Add to Collection

Article Genetics & Heredity

Evolution of Streptococcus pneumoniae Serotype 3 in England and Wales: A Major Vaccine Evader

Natalie Groves et al.

GENES (2019)

Add to Collection

Article Public, Environmental & Occupational Health

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices

Almea Matanock et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2019)

Add to Collection

Review Immunology

Impact of the 13-Valent Pneumococcal Conjugate Vaccine Among Adults: A Systematic Review and Meta-analysis

Nirma Khatri Vadlamudi et al.

CLINICAL INFECTIOUS DISEASES (2019)

Add to Collection

Article Immunology

The Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage in the Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Study

Anna M. M. van Deursen et al.

CLINICAL INFECTIOUS DISEASES (2018)

Add to Collection

Article Infectious Diseases

Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study

Shamez N. Ladhani et al.

LANCET INFECTIOUS DISEASES (2018)

Add to Collection

Article Public, Environmental & Occupational Health

Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15

Brian Wahl et al.

LANCET GLOBAL HEALTH (2018)

Add to Collection

Review Public, Environmental & Occupational Health

Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis

Tinevimbo Shiri et al.

LANCET GLOBAL HEALTH (2017)

Add to Collection

Article Infectious Diseases

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

Matthew R. Moore et al.

LANCET INFECTIOUS DISEASES (2015)

Add to Collection

Article Medicine, General & Internal

Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults

M. J. M. Bonten et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Review Medicine, Research & Experimental

Recommendations for Pneumococcal Immunization Outside Routine Childhood Immunization Programs in Western Europe

Paolo Castiglia

ADVANCES IN THERAPY (2014)

Add to Collection

Review Infectious Diseases

Pneumococcal infection in adults: burden of disease

J. J. C. Drijkoningen et al.

CLINICAL MICROBIOLOGY AND INFECTION (2014)

Add to Collection

Review Immunology

Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults

John D. Grabenstein et al.

VACCINE (2014)

Add to Collection

Review Infectious Diseases

Pneumococcal vaccine and opsonic pneumococcal antibody

Joon Young Song et al.

JOURNAL OF INFECTION AND CHEMOTHERAPY (2013)

Add to Collection

Review Multidisciplinary Sciences

Estimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic Techniques

Maria A. Said et al.

PLOS ONE (2013)

Add to Collection

Article Immunology

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Lisa A. Jackson et al.

VACCINE (2013)

Add to Collection

© Peeref 2019-2024. All rights reserved.